Treatment News : Strategies for a Cure Reviewed in Vienna - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 19, 2010

Strategies for a Cure Reviewed in Vienna

by Tim Horn

True to tradition, several world-renowned key opinion leaders opened this year’s International AIDS Conference, being held July 18 to 23 in Vienna, with a detailed review of the state of the HIV epidemic. Among the speakers was Sharon Lewin, FRACP, PhD, director of the infectious diseases unit at The Alfred Hospital in Melbourne, Australia, who made a provocative call to move full-steam ahead with strategies to cure HIV.


XVIII International AIDS Conference (AIDS 2010). Opening Press Conference. Sharon Lewin, Director of the Infectious Diseases Unit at The Alfred Hospital, Professor of Medicine at Monash University in Melbourne, and Co-Director of the Centre for Virology, Burnet Institute
©IAS/Steve Forrest/Workers' Photos


Though researchers, health care providers and people living with HIV—working in tandem—have made considerable progress in the prevention, care and treatment of the virus, Lewin noted that life expectancy following HIV infection, even under the best of circumstances, remains below that of those who are HIV negative. She also noted that antiretroviral (ARV) therapy continues to bear significant side effects and that higher rates of comorbidities, such as cardiovascular disease and cancers, continue to be documented among people living with HIV. Additionally, on a global scale, for every two people started on ARV treatment, five new HIV infections occur. 

Finding a cure for HIV is feasible, Lewin noted. She illustrated the case of a Berlin patient living with HIV and acute myeloid leukemia who underwent high-dose chemotherapy and total body irradiation, followed by a stem cell transplant involving donor cells with the CCR5-delta32 deletion—cells incapable of expressing CCR5, one of the main HIV receptors on lymphocytes and macrophages. The patient, Lewin reports, has remained negative for HIV since his transplant in 2008 and has not resumed antiretroviral therapy.

There are two distinct types of cures that may be possible in people living with HIV. First there is the sterilizing cure, where the goal is to completely eliminate all HIV from the body. The second possibility is a functional cure, where HIV remains completely suppressed—but is still present—without the need for ongoing ARV treatment.

Achieving either of these goals will not be easy, Lewin said, pointing out three key scientific challenges. First and most challenging is the persistence of latent HIV infection—inactive cells harboring the virus that cannot be targeted by available ARVs. Second, there is residual replication by these cells, even when the most potent ARV regimens are used. Finally, some anatomical sites—notably the central nervous system, the gut and genital tract—are not easily reached by many of today’s ARVs.

Strategies to circumvent these obstacles are currently being explored. One possibility highlighted by Lewin, drawing upon data published by a Spanish team of researchers, involves intensifying ARV treatment. This approach showed potential promise using Merck’s Isentress (raltegravir), according to the paper published earlier this year in Nature Medicine.

Another approach is to reduce the pools of latently infected cells through earlier treatment and by using medications such as interleukin-7 and histone deacetylase inhibitors.

Another possibility is using genetic therapies, such as modifying stem cells or delivering genes using a vector, to knock out CCR5, one of two major co-receptors used by HIV to infect CD4 cells.

Lewin noted that although these particular strategies are still in the proof-of-concept stage of development, they are grounds for optimism. She also pointed out that cure-based treatment approaches will be a major theme throughout the weeklong conference.

Search: cure, eradication, CCR5, latent HIV, Lewin, Vienna, International AIDS Conference

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (13 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.